Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood ...

Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Lexeo Therapeutics announces positive interim phase 1/2 data for LX2006 in Friedreich ataxia cardiomyopathy: New York Wednesday, April 9, 2025, 12:00 Hrs [IST] Lexeo Therapeutics, ...

The firm plans to use improvement in left ventricular mass index and increased frataxin protein expression after LX2006 treatment as co-primary endpoints.

Lexeo Therapeutics, Inc.’s LXEO share price has surged by 9.50%, which has investors questioning if this is right time to ...

“We are pleased to share further regulatory clarity for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, and we appreciate the continued partnership from the FDA on an ...

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 9.71%, which has investors questioning if this is right time to buy ...

interim clinical data update expected in second half of 2025 “We are pleased to share further regulatory clarity for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy ...